Early thrombocytopenia predicts longer time‑to‑treatment discontinuation in trastuzumab emtansine treatment

Thrombocytopenia is a characteristic adverse event of trastuzumab emtansine (T-DM1), one of the essential treatment options for human epithelial growth factor receptor 2 (HER2)-positive breast cancer. The present study investigated the predictive value of thrombocytopenia for time-to-treatment disco...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2023-12, Vol.26 (6), p.1, Article 523
Main Authors: Sahin, Ahmet Bilgehan, Caner, Burcu, Ocak, Birol, Gulmez, Ahmet, Hamitoglu, Buket, Cubukcu, Erdem, Deligonul, Adem, Orhan, Sibel Oyucu, Canhoroz, Mustafa, Odman, Hikmet Utku, Somali, Isil, Ocakoglu, Gokhan, Evrensel, Turkkan
Format: Article
Language:English
Subjects:
Breast cancer
Cancer
Development and progression
Drug dosages
Estrogens
FDA approval
Medical research
Metastasis
Mortality
Oncology
Oncology, Experimental
Pertuzumab
Regression analysis
Thrombocytopenia
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thrombocytopenia is a characteristic adverse event of trastuzumab emtansine (T-DM1), one of the essential treatment options for human epithelial growth factor receptor 2 (HER2)-positive breast cancer. The present study investigated the predictive value of thrombocytopenia for time-to-treatment discontinuation (TTD) in patients receiving T-DM1 for advanced-stage HER2-positive breast cancer. The present observational study enrolled 138 patients who received T-DM1 at six oncology centers from January 2016 to December 2021. Univariate and multivariate Cox regression analyses were performed to determine the factors affecting TTD. The median age of patients was 50 years (range, 26-83). The median number of T-DM1 cycles was 9 (range, 2-58), the overall response rate was 50.0% and the disease control rate was 69.6%. At a median follow-up time of 19.3 months, the median TTD was 9.5 months [95% confidence interval (CI), 7.3-11.7], and the median overall survival was 28.2 months (95% CI, 19.2-37.2). Thrombocytopenia during treatment was observed in 39% of all patients, and 66.7% of these patients experienced early thrombocytopenia (in the first four treatment cycles). Multivariate analysis revealed that the independent factors for TTD were hormone receptor status [hazard ratio (HR), 1.837; 95% CI, 1.249-2.701; P=0.002], Eastern Cooperative Oncology Group performance status score (HR, 3.269; 95% CI, 1.788-5.976; P
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2023.14110